Caliber Wealth Management LLC KS Decreases Stake in REGENXBIO Inc. $RGNX

Caliber Wealth Management LLC KS lowered its position in REGENXBIO Inc. (NASDAQ:RGNX) by 8.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,095 shares of the biotechnology company’s stock after selling 1,493 shares during the quarter. Caliber Wealth Management LLC KS’s holdings in REGENXBIO were worth $132,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in REGENXBIO by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 27,756 shares of the biotechnology company’s stock worth $198,000 after acquiring an additional 2,326 shares during the last quarter. Brooklyn Investment Group lifted its stake in REGENXBIO by 163.7% in the first quarter. Brooklyn Investment Group now owns 5,583 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 3,466 shares during the last quarter. American Century Companies Inc. lifted its stake in REGENXBIO by 6.9% in the first quarter. American Century Companies Inc. now owns 101,579 shares of the biotechnology company’s stock worth $726,000 after acquiring an additional 6,553 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in REGENXBIO by 67.1% in the second quarter. Pallas Capital Advisors LLC now owns 17,407 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 6,992 shares during the last quarter. Finally, Corton Capital Inc. lifted its stake in REGENXBIO by 54.6% in the first quarter. Corton Capital Inc. now owns 20,528 shares of the biotechnology company’s stock worth $147,000 after acquiring an additional 7,252 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Royal Bank Of Canada reduced their price objective on shares of REGENXBIO from $21.00 to $17.00 and set an “outperform” rating for the company in a research report on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research report on Wednesday, October 8th. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Monday, September 8th. HC Wainwright restated a “buy” rating and set a $34.00 price objective on shares of REGENXBIO in a research report on Tuesday, October 7th. Finally, Wall Street Zen downgraded shares of REGENXBIO from a “hold” rating to a “strong sell” rating in a research report on Saturday, August 9th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.38.

Insider Activity at REGENXBIO

In other news, CEO Curran Simpson sold 20,811 shares of REGENXBIO stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $12.62, for a total value of $262,634.82. Following the transaction, the chief executive officer directly owned 216,162 shares of the company’s stock, valued at $2,727,964.44. The trade was a 8.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have sold 36,169 shares of company stock valued at $416,598. Insiders own 12.79% of the company’s stock.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $12.19 on Thursday. The firm’s fifty day simple moving average is $9.90 and its 200-day simple moving average is $8.93. The stock has a market capitalization of $615.72 million, a price-to-earnings ratio of -3.54 and a beta of 1.17. REGENXBIO Inc. has a 12 month low of $5.03 and a 12 month high of $13.39.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($1.13) by ($0.25). The business had revenue of $21.36 million during the quarter, compared to analyst estimates of $40.87 million. REGENXBIO had a negative net margin of 112.70% and a negative return on equity of 66.95%. Analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.